Estimaciones de analistas de Wall Street para ProQR Therapeutics N.V. (PRQR): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 1 |
| Compra | 10 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 12 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.11 | ||
| 2026-08-13 | $-0.10 | $-0.13 | +23.2% |
| 2026-05-12 | $-0.15 | $-0.15 | +0.0% |
| 2026-03-12 | $-0.09 | $-0.08 | -12.5% |
| 2025-11-06 | $-0.12 | $-0.10 | -20.0% |
| 2025-08-07 | $-0.14 | $-0.08 | -75.0% |
| 2025-05-08 | $-0.11 | $-0.09 | -22.2% |
| 2025-03-13 | $-0.10 | $-0.10 | +0.0% |
Ratios de valoración
| Precio / Valor contable | 2.09 |
| EV / EBITDA | -2.27 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $2.3M | -$1.5M | $4.9M | $1.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $15.3M |
| Coste de Ventas | $1.3M | $1.0M | $983511 | $116.8M | 0 | 0 | 0 | 0 | 0 | $2.6M |
| Beneficio Bruto | $1.0M | -$2.5M | $4.0M | -$114.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $12.7M |
| I+D | $31.9M | $31.2M | $29.5M | $46.5M | $38.1M | $42.2M | $50.9M | $25.1M | $36.4M | $40.7M |
| Generales y Administrativos | $9.5M | $10.8M | $12.5M | $12.9M | $13.7M | $17.4M | $18.7M | $16.2M | $13.7M | $15.1M |
| Gastos Operativos | $41.4M | $42.0M | $42.1M | $59.4M | $43.4M | $58.5M | $68.8M | $38.4M | $49.4M | $54.8M |
| Beneficio Operativo | -$39.6M | -$40.5M | -$36.3M | -$57.4M | -$42.4M | -$57.2M | -$65.2M | -$31.9M | -$30.5M | -$42.2M |
| EBITDA | -$120.5M | 0 | -$35.3M | -$174.3M | -$48.4M | -$54.9M | -$56.5M | -$24.1M | -$24.1M | -$37.0M |
| Gastos por Intereses | $538000 | $596000 | $810000 | $1.1M | $2.0M | $3.4M | $5.1M | $1.2M | $1.1M | $866400 |
| Beneficio Antes de Impuestos | -$39.1M | -$43.7M | -$37.1M | -$56.6M | -$46.5M | -$60.7M | -$64.1M | -$27.8M | -$28.0M | -$40.5M |
| Impuestos | 0 | $2000 | $1000 | $132000 | $124000 | $117000 | $96000 | -$78000 | -$197000 | $18249 |
| Beneficio Neto | -$39.1M | -$43.6M | -$36.9M | -$56.7M | -$46.6M | -$60.7M | -$64.4M | -$28.1M | -$27.8M | -$40.5M |
| BPA | $-1.67 | $-1.72 | $-1.08 | $-1.38 | $-0.93 | $-0.96 | $-0.91 | $-0.35 | $-0.34 | $-0.38 |
| BPA Diluido | $-1.67 | $-1.72 | $-1.08 | $-1.38 | $-0.93 | $-0.96 | $-0.91 | $-0.35 | $-0.34 | $-0.38 |
| Acciones en Circulación (Diluidas) | $23.3M | $25.4M | $34.1M | $41.0M | $50.1M | $64.2M | $71.6M | $81.0M | $81.7M | $105.3M |
Precio
| Precio | $1.86 |
| Capitalización | $196M |
| Bolsa | NASDAQ |
| País | NL |
Empresas relacionadas: ACHV · ALLO · ARCT · CAPR · EDIT · IMMP · MREO
Explorar sector: Healthcare · Biotechnology
Más secciones de PRQR: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones